Stephen Eeden to Prostatic Hyperplasia
This is a "connection" page, showing publications Stephen Eeden has written about Prostatic Hyperplasia.
Connection Strength
0.868
-
The Use of 5-Alpha Reductase Inhibitors to Manage Benign Prostatic Hyperplasia and the Risk of All-cause Mortality. Urology. 2018 Sep; 119:70-78.
Score: 0.320
-
5-Alpha Reductase Inhibitors and the Risk of Prostate Cancer Mortality in Men Treated for Benign Prostatic Hyperplasia. Mayo Clin Proc. 2016 Dec; 91(12):1717-1726.
Score: 0.286
-
Contribution of common medications to lower urinary tract symptoms in men. Arch Intern Med. 2011 Oct 10; 171(18):1680-2.
Score: 0.201
-
Progression and treatment of incident lower urinary tract symptoms (LUTS) among men in the California Men's Health Study. BJU Int. 2015 Jan; 115(1):127-33.
Score: 0.061